Konishi N - Search Results

1

Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor.

Fujimoto T, Imaeda Y, Konishi N, Hiroe K, Kawamura M, Textor GP, Aertgeerts K, Kubo K. Fujimoto T, et al. Among authors: konishi n. J Med Chem. 2010 May 13;53(9):3517-31. doi: 10.1021/jm901699j. J Med Chem. 2010. PMID: 20355714

2

Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.

Imaeda Y, Miyawaki T, Sakamoto H, Itoh F, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Imaeda Y, et al. Among authors: konishi n. Bioorg Med Chem. 2008 Mar 1;16(5):2243-60. doi: 10.1016/j.bmc.2007.11.073. Epub 2007 Dec 3. Bioorg Med Chem. 2008. PMID: 18077174

3

Discovery of piperazinylimidazo[1,2-a]pyridines as novel S4 binding elements for orally active factor Xa inhibitors.

Imaeda Y, Kawamoto T, Tobisu M, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Imaeda Y, et al. Among authors: konishi n. Bioorg Med Chem. 2008 Mar 15;16(6):3125-40. doi: 10.1016/j.bmc.2007.12.024. Epub 2007 Dec 27. Bioorg Med Chem. 2008. PMID: 18164204

4

Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.

Imaeda Y, Kuroita T, Sakamoto H, Kawamoto T, Tobisu M, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K. Imaeda Y, et al. Among authors: konishi n. J Med Chem. 2008 Jun 26;51(12):3422-36. doi: 10.1021/jm701548u. Epub 2008 May 29. J Med Chem. 2008. PMID: 18507371

5

Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one.

Fujimoto T, Tobisu M, Konishi N, Kawamura M, Tada N, Takagi T, Kubo K. Fujimoto T, et al. Among authors: konishi n. Bioorg Med Chem. 2009 Dec 1;17(23):7993-8002. doi: 10.1016/j.bmc.2009.10.009. Epub 2009 Oct 14. Bioorg Med Chem. 2009. PMID: 19861238

6

Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.

Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, Kubo K. Kawamura M, et al. Among authors: konishi n. J Cardiovasc Pharmacol. 2010 Aug;56(2):156-61. doi: 10.1097/FJC.0b013e3181e2bfcf. J Cardiovasc Pharmacol. 2010. PMID: 20410831

7

Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats.

Konishi N, Hiroe K, Kawamura M. Konishi N, et al. Thromb Res. 2010 Aug;126(2):124-9. doi: 10.1016/j.thromres.2010.04.005. Epub 2010 May 10. Thromb Res. 2010. PMID: 20452654

8

Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.

Konishi N, Hiroe K, Kawamura M. Konishi N, et al. Thromb Haemost. 2010 Sep;104(3):504-13. doi: 10.1160/TH09-12-0817. Epub 2010 Jul 20. Thromb Haemost. 2010. PMID: 20664909

9

Effects of fondaparinux and a direct factor Xa inhibitor TAK-442 on platelet-associated prothrombinase in the balloon-injured artery of rats.

Konishi N, Hiroe K, Kawamura M. Konishi N, et al. J Cardiovasc Pharmacol. 2011 Feb;57(2):201-6. doi: 10.1097/FJC.0b013e31820382a9. J Cardiovasc Pharmacol. 2011. PMID: 21052010

10

[Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].

Konishi N, Hiroe K, Kawamura M. Konishi N, et al. Nihon Yakurigaku Zasshi. 2010 Aug;136(2):88-92. doi: 10.1254/fpj.136.88. Nihon Yakurigaku Zasshi. 2010. PMID: 20702967 Review. Japanese. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

592 results

Search Page

Filters